...
首页> 外文期刊>Journal of Medicinal Chemistry >Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5- carbonitrile) analogues at monoamine transporters
【24h】

Structure-activity relationships for a novel series of citalopram (1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5- carbonitrile) analogues at monoamine transporters

机译:新型西酞普兰(1-(3-(二甲基氨基)丙基)-1-(4-氟苯基)-1,3-二氢异苯并呋喃-5-腈)类似物在单胺转运蛋白上的结构-活性关系

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

(±)-Citalopram (1, 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)-1, 3-dihydroisobenzofuran-5-carbonitrile), and its eutomer, escitalopram (S-(+)-1) are selective serotonin reuptake inhibitors (SSRIs) that are used clinically to treat anxiety and depression. To further explore structure-activity relationships at the serotonin transporter (SERT), a series of (±)-4- and 5-substituted citalopram analogues were designed, synthesized, and evaluated for binding at the SERT, dopamine transporter (DAT) and norepinephrine transporter (NET) in native rodent tissue. Many of these analogues showed high SERT binding affinities (K_i = 1-40 nM) and selectivities over both NET and DAT. Selected enantiomeric pairs of analogues were synthesized and both retained enantioselectivity as with S- and R-1, wherein S > R at the SERT. In addition, the enantiomeric pairs of 1 and 5 were tested for binding at the homologous bacterial leucine transporter (LeuT), wherein low affinities and the absence of enantioselectivity suggested distinctive binding sites for these compounds at SERT as compared to LeuT. These novel ligands will provide molecular tools to elucidate drug-protein interactions at the SERT and to relate those to behavioral actions in vivo.
机译:(±)-西酞普兰(1,1-(3-(二甲基氨基)丙基)-1-(4-氟苯基)-1,3-二氢异苯并呋喃-5-甲腈)及其eutomer依他普仑(S-(+)- 1)是选择性5-羟色胺再摄取抑制剂(SSRI),在临床上用于治疗焦虑和抑郁。为了进一步探讨5-羟色胺转运蛋白(SERT)的结构活性关系,设计,合成了一系列(±)-4-和5-取代的西酞普兰类似物,并评估了在SERT,多巴胺转运蛋白(DAT)和去甲肾上腺素的结合天然啮齿动物组织中的转运蛋白(NET)。这些类似物中的许多在NET和DAT上均显示出很高的SERT结合亲和力(K_i = 1-40 nM)和选择性。合成选择的对映体对类似物对,并且都保留与S-和R-1一样的对映体选择性,其中SERT处的S> R。另外,测试了1和5的对映异构体对在同源细菌亮氨酸转运蛋白(LeuT)上的结合,其中低亲和力和不存在对映选择性表明,与LeuT相比,这些化合物在SERT处具有独特的结合位点。这些新的配体将提供分子工具,以阐明SERT处的药物-蛋白质相互作用,并将其与体内的行为行为联系起来。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号